Low Risk of Safety, Efficacy Concerns After Switching to a Biosimilar
March 6th 2018In an effort to evaluate whether switching from a reference biologic to a biosimilar could lead to altered clinical outcome, a research team, led by Hillel Cohen, PhD, conducted a systematic literature review of all available switching studies.
Read More
FDA Advisory Committee Discusses 2018-2019 Flu Vaccine Strains
March 4th 2018WHO officials noted that “recent A(H3N2) viruses were better inhibited by ferret antisera raised against the egg-propagated reference virus A/Singapore/INFIMH-16-0019/2016 compared to ferret antisera raised against other recent egg-propagated A(H3N2) viruses.”
Read More